Roswell Park Study First to Show Two-Drug Combination Selectively Targets p53-Mutant Cancers
A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers.
26-Feb-2024 11:30 AM EST
Add to Favorites